European regulators have recommended Rasonque, an oral cancer medicine, for adults with pancreatic cancer that has spread and worsened after at least one previous systemic treatment. The recommendation is an important step towards potential use across the European Union, but it is not yet a marketing authorisation.
The recommendation, adopted on 15 October, covers Rasonque as a single-agent treatment for metastatic pancreatic adenocarcinoma. The medicine’s active substance is daraxonrasib. The proposed indication is for adults who have received at least one prior systemic therapy. The European Commission must still decide whether to grant an EU-wide marketing authorisation. National decisions on price and reimbursement would follow separately.
Trial results behind the recommendation
The recommendation followed a review of a multinational, open-label phase 3 trial involving 500 people whose metastatic pancreatic adenocarcinoma had worsened after previous treatment. Participants were assigned to receive daraxonrasib or a chemotherapy regimen selected by their investigators. The trial was designed to compare survival and the length of time before disease progression.
In the analysis cited in the regulatory assessment, median overall survival was 12.4 months for patients receiving daraxonrasib and 6.7 months for those receiving chemotherapy. Median progression-free survival was 7.2 months and 3.6 months respectively. Overall survival measures the time patients lived after entering the study; progression-free survival measures time before the disease worsened or death.
These are group medians, not a prediction of how long any individual patient will live. The figures do not mean every person receiving the medicine lived longer than every person receiving chemotherapy. The results came from a trial in people with advanced disease after prior treatment, and should not be taken as evidence about use in other settings or earlier stages.
The trial was open-label, meaning participants and clinicians knew which treatment was being given. The primary survival analysis used data collected up to 15 June 2026; the progression-free survival analysis used data up to 10 February 2026. The committee’s recommendation is an assessment of the available evidence, not a guarantee of benefit for every patient.
A faster assessment route
The review was conducted in phases, allowing the committee to begin examining quality, non-clinical and clinical information as it was submitted rather than waiting for a complete application. Assessment began in early July 2026 and took fewer than 150 days. A standard evaluation can involve up to 210 active assessment days and generally takes longer overall because the applicant must respond to questions.
The phased process was used because the medicine was considered a high priority for an unmet medical need. The approach changes the timing of the regulatory review; it does not remove the requirements to assess quality, safety and effectiveness. Regulators have said lessons from this review will inform how phased assessments are used under the revised EU medicines framework. Further use is to be considered case by case.
Potential benefits and known risks
Daraxonrasib works by binding to cyclophilin A, forming a complex that interferes with RAS signalling involved in cancer-cell growth. The most commonly reported side effects in the assessment were diarrhoea, rash, inflammation of the mouth, nausea and vomiting. Detailed instructions for use will be set out in product information if the Commission grants authorisation.
For eligible patients and clinicians, the next regulatory step is the Commission’s decision. Even if authorisation is granted, availability and reimbursement will depend on national processes. The recommendation does not itself mean the treatment is immediately available throughout Europe.
